OcrelizumabCOVID-19 infection: 2 case reports

被引：0

|

作者：

机构：

来源：

Reactions Weekly | 2023年 / 1950卷 / 1期

关键词：

D O I：

10.1007/s40278-023-36718-6

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：321 / 321

相关论文

共 50 条

[1] OcrelizumabCOVID-19 infection: case report
Reactions Weekly, 2022, 1928 (1) : 297 - 297
[2] Alemtuzumab/natalizumab/ocrelizumabCOVID-19: 3 case reports
Reactions Weekly, 2021, 1882 (1) : 34 - 34
[3] RituximabCOVID-19 infection: 2 case reports
Reactions Weekly, 2020, 1833 (1) : 342 - 342
[4] HydroxychloroquineCOVID-19 infection: 2 case reports
Reactions Weekly, 2020, 1813 (1) : 120 - 120
[5] RituximabCOVID-19 infection: 2 case reports
Reactions Weekly, 2022, 1897 (1) : 324 - 324
[6] ImmunosuppressantsCOVID-19 infection: 2 case reports
Reactions Weekly, 2021, 1841 (1) : 127 - 127
[7] Ocrelizumab/rituximabCOVID-19 infection: 2 case reports
Reactions Weekly, 2021, 1870 (1) : 258 - 258
[8] Baclofen/temazepamCOVID-19 infection: 2 case reports
Reactions Weekly, 2023, 1938 (1) : 301 - 301
[9] Carboplatin/pemetrexedCOVID-19 infection: 2 case reports
Reactions Weekly, 2021, 1850 (1) : 91 - 91
[10] AntineoplasticsCOVID-19 infection: 19 case reports
Reactions Weekly, 2022, 1937 (1) : 55 - 55

← 1 2 3 4 5 →